{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017846","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.348130+00:00","generated_at":"2026-06-15T23:04:19.838331+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tyra Biosciences Q1 net loss $11.9M, cash $241.7M; programs advance","bullets":["Net loss $11.9M vs $14.8M YoY; R&D expense $10.4M, G&A $3.9M.","Cash and equivalents $241.7M, expected to fund operations >2 years.","SURF301 Phase 1/2 of TYRA-300 for FGFR3+ tumors continues enrolling patients.","TYRA-300 development expanded into achondroplasia; IND submission targeted in 2024.","TYRA-200 IND cleared by FDA; Phase 1 for cholangiocarcinoma on track for 2H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017846","json":"https://secwatch.observer/filing/0000950170-23-017846.json","markdown":"https://secwatch.observer/filing/0000950170-23-017846.md","text":"https://secwatch.observer/filing/0000950170-23-017846.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000095017023017846/0000950170-23-017846-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000095017023017846/tyra-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T23:04:19.838331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4b67f16be4639cf1447f7a4415838b13679b6783","claim":"Tyra Biosciences, Inc. reported the quarter ended March 31, 2023 results: net income $11.9 million.","evidence_excerpt":"Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017023017846/0000950170-23-017846-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"$11.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}